Asceneuron scoops One Nucleus BioNewsRound Award

30.12.2015 11:24

Asceneuron is this year’s winner of the coveted One Nucleus BioNewsRound Award. The Swiss start-up has prevailed over five nominees including Astra Zeneca and Immunocore.

Harriet Fear, CEO of One Nucleus, described competition as fierce, with the votes having been cast by the sector in an on-line, and therefore peer reviewed, open voting process.

“The winner is a fantastic example of what can be achieved when brilliant science, a collaborative spirit and a fantastic team come together,” said Harriet Fear. “The criteria for the Award are about great impact on and for the company, the sector and most importantly of all - the patient. We were overwhelmed by the response to the Award, which recognises not only the impact of the project, but also how well it was communicated to the sector at large.”

”Asceneuron’s ASN-561 inhibitor of the O-GlcNAcase enzyme has been shown in preclinical models to reduce the build-up of toxic neurofibrillary tangles consisting of tau protein in the brain” explains Dr. Dirk Beher, Chief Executive Officer and a co-founder of Asceneuron. “If shown to be safe and tolerated this molecule will enable us to explore ASN-561 as a potential drug for a variety of diseases caused by these neurofibrillary tangles. We are thrilled by the Award in recognition of the hard work the team has put into ultimately bringing innovation to patients in an area of high unmet medical need” he added.

“We are delighted to see that the achievements of Asceneuron, through its ground breaking work on tau-related diseases, along with the recent sizeable financing, with Sofinnova Partners, SR One, Johnson & Johnson Innovation - JJDC and Kurma Partners joining us, have helped earn this prestigious award.” said Dr. Hakan Goker, Senior Investment Director at MS Ventures, the strategic corporate venture capital fund of the healthcare business of Merck.

(SK)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.